Publications by authors named "Chris Lascola"
Clin Cancer Res
January 2023
Article Synopsis
- Brain metastases can affect up to 50% of patients with HER2-positive breast cancer, but past trials mostly excluded those with active brain metastases, leading to limited understanding of the antibody-drug conjugate T-DXd's effectiveness in this area.
- T-DXd was tested in both patient-derived xenografts of HER2-positive and HER2-low breast cancer brain metastases and a retrospective study of 17 patients, showing significant tumor growth inhibition and improved survival rates.
- Results indicated a 73% CNS objective response rate in patients with primarily HER2-positive brain metastases, suggesting promising CNS activity of T-DXd and the need for future clinical trials to assess its efficacy further.
